



HIGH FREQUENCY CHEST WALL OSCILLATION (HFCWO) THERAPY SHOWS REDUCTION IN HEALTHCARE RESOURCE UTILIZATION

In an independent, retrospective cohort analysis conducted on patients with Non-Cystic Fibrosis Bronchiectasis (NCFB) who utilized HFCWO, experienced improved health outcomes as well as a reduction in Healthcare Resource Utilization (HCRU), after HFCWO as compared to before.¹

Background of Study

The analysis was conducted on NCFB patients who received HFCWO therapy using the IQVIA® PharMetrics Plus® for MedTech, one of the largest US health plan databases of adjudicated integrated medical and pharmacy claims.

Patients were required to have evidence of receiving HFCWO within a one-year period. The study aimed to understand patient characteristics and compare HCRU and outcomes (both before and after receipt of HFCWO) among patients with NCFBE.

Results of the Study:

Prior to using HFCWO, patients reported experiencing bronchiectasis-related exacerbations, pulmonary hospitalizations, and outpatient HCRU. After using HFCWO, key health outcomes improved, while outpatient resource utilization decreased.¹



REDUCTION IN
HOSPITALIZATIONS




REDUCTION IN
MEDICATION USE



REDUCTION IN
OUTPATIENT RESOURCES

SEE MORE RESULTS >>


Significant Decrease in HCRU = Lower Outpatient Costs



	Pre-index		Post-index		p-value*
	n	%	n	%	
Outpatient Resources					
Chest x-ray	77	76.2	52	51.5	<.0001
CT scan	76	75.2	39	38.6	<.0001
Lung function test	78	77.2	49	48.5	<.0001
Smear gram stain	29	28.7	14	13.9	<.0018

Following HFCWO therapy, outpatient healthcare resource utilization and medication use decreased, generating a greater cost savings.^{1*}

Reduction in Bronchiectasis Symptoms



	Pre-index		Post-index		p-value*
	n	%	n	%	
Outcomes					
Bronchiectasis exacerbations†	43	42.6	33	32.7	0.0679
Cough	61	60.4	49	48.5	0.0455
Hospitalizations (all-cause)	39	38.6	20	19.8	0.0023
Pneumonia	45	44.6	27	26.7	0.001
Pulmonary hospitalizations	35	34.7	19	18.8	0.0094

Following HFCWO therapy, key health outcomes improved, as patients reported experiencing a reduction in pulmonary hospitalizations, cough, and pneumonia.¹

What This Study Means for NCFBE Patients

NCFBE patients who use HFCWO therapy as part of their treatment for managing bronchiectasis-related symptoms can improve their health outcomes overtime while reducing the need for outpatient resources, which can translate to a potential cost savings.

Electromed is pleased to further the body of evidence in support of HFCWO therapy and SmartVest, continuously showing improved patient outcomes. For further information, visit smartvest.com

Make SmartVest Part of Your Treatment Plan!

Contact us at **800-462-1045** to get started prescribing SmartVest or visit **smartvest.com** to learn more about using SmartVest and how it can benefit your patients’ bronchiectasis treatment plan.

¹ DeKoven M, Mandia K, DeFabis N, Chen J, Ruscio A. Patient characteristics, healthcare resource utilization and outcomes among non-cystic fibrosis bronchiectasis patients with high frequency chest wall oscillation (HFCWO) therapy. IQVIA PharMetrics Plus for MedTech. 2018-2019.

*Hospitalizations among NCFBE patients who develop an infection cost up to \$36,665 compared to \$20,421 for a hospitalization prior to infection.

MD, KM, ND, JC and AR are all employees of IQVIA, which received funding for this study from Electromed, Inc. “IQVIA” and “PharMetrics Plus” is a registered trademark of IQVIA, Inc. “SmartVest” is a registered trademark of Electromed, Inc. EM00629.2022-05